Recommendations for User Fee Programs: Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 Through 2017; Meeting
Document ID: FDA-2011-N-0326-0024
Comments
Total: 12
-
Pharmaceutical Research and Manufacturers of America (PhRMA) - Testimony
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0025 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
Academy of Managed Care Pharmacy (AMCP) - Comment
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0026 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
Shein-Chung Chow, PhD Duke University School of Medicine - Testimony
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0027 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
BIO - Testimony
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0028 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
Alliance for Safe Biologic Medicines - Comment
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0030 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
Bruce A. Leicher, Momenta Pharmaceuticals, Inc. - Testimony
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0031 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
Pfizer Inc - Comment
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0032 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
Global Healthy Living Foundation - Comment
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0033 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
AARP - Comment
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0034 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
American Association of People with Disabilities - Comment
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0035 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
Biotechnology Industry Organization (BIO) - Comment
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0036 Agency : FDA -
Jan 06,2012 11:59 PM ET
-
Reliance Life Sciences, Inc. - Comment
Posted : 01/11/2012 ID ：FDA-2011-N-0326-0037 Agency : FDA -
Jan 06,2012 11:59 PM ET